-
1.发明授权Method for detecting muscle degenerative diseases, and method for determining therapeutic efficacy on the diseases 有权检测肌肉退行性疾病的方法，以及确定疾病治疗功效的方法公开(公告)号：US08658390B2
公开(公告)日：2014-02-25
申请号：US13255120
申请日：2010-03-08
申请人： Yoshihiro Urade , Kosuke Aritake , Toshihiko Maruyama , Shinya Kamauchi , Shin'ichi Takeda , Akinori Nakamura
发明人： Yoshihiro Urade , Kosuke Aritake , Toshihiko Maruyama , Shinya Kamauchi , Shin'ichi Takeda , Akinori Nakamura
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N30/7233 , G01N2030/8813 , G01N2800/28 , G01N2800/2878
摘要： Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.
摘要翻译： 可以在早期检测肌肉退行性疾病，治疗剂的治疗效果和/或治疗方法可以通过测量11,15-二氧代-9α-羟基-2,3,4,5-四 在受试者分离的样品中的四前驱体-1,20-二酸（以下称为“Tetranor-PGDM”）。
-
2.发明申请METHOD FOR DETECTING MUSCLE DEGENERATIVE DISEASES, AND METHOD FOR DETERMINING THERAPEUTIC EFFICACY ON THE DISEASES 有权检测肌肉退行性疾病的方法，以及确定疾病治疗效果的方法公开(公告)号：US20110318764A1
公开(公告)日：2011-12-29
申请号：US13255120
申请日：2010-03-08
申请人： Yoshihiro Urade , Kosuke Aritake , Toshihiko Maruyama , Shinya Kamauchi , Shin'ichi Takeda , Akinori Nakamura
发明人： Yoshihiro Urade , Kosuke Aritake , Toshihiko Maruyama , Shinya Kamauchi , Shin'ichi Takeda , Akinori Nakamura
CPC分类号： G01N33/6893 , G01N30/7233 , G01N2030/8813 , G01N2800/28 , G01N2800/2878
摘要： Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.
摘要翻译： 可以在早期检测肌肉退行性疾病，治疗剂的治疗效果和/或治疗方法可以通过测量11,15-二氧代-9α-羟基-2,3,4,5-四氢 - 在受试者分离的样品中的四前驱体-1,20-二酸（以下称为“Tetranor-PGDM”）。
-
3.发明申请Method for treating myolytic disease and method for screening antimyolytic agent 失效治疗溶血性疾病的方法和抗溶血剂筛选方法公开(公告)号：US20050272767A1
公开(公告)日：2005-12-08
申请号：US10919473
申请日：2004-08-17
申请人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Yo Sato , Masako Taniike , Ikuko Mori , Masashi Miyano
发明人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Yo Sato , Masako Taniike , Ikuko Mori , Masashi Miyano
IPC分类号： G01N33/50 , A01K67/027 , A01N25/00 , A01N43/42 , A61K31/185 , A61K31/403 , A61K31/4166 , A61K31/454 , A61K31/47 , A61K31/501 , A61K31/53 , A61K45/00 , A61P3/10 , A61P9/10 , A61P21/00 , A61P21/04 , A61P43/00 , C12N15/85 , C12N15/90 , G01N33/15
CPC分类号： G01N33/5088 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K31/47 , C12N15/8509 , C12N15/90 , G01N2800/2892 , G01N2800/324 , G01N2800/325
摘要： An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic prostaglandin D synthase (H-PGDS) or an antagonist to prostaglandin D receptor is administered to a patient who needs it. The present invention also provides a method for screening compounds which are able to prevent the progress of myolytic diseases and to improve it using human H-PGDS overexpressed transgenic mice.
摘要翻译： 本发明的目的是提供能够防止或改善诸如肌营养不良症的肌溶解性疾病进展的方法。 能够通过以下方法解决这样的问题：将有效剂量的造血前列腺素D合成酶（H-PGDS）抑制剂或前列腺素D受体拮抗剂的有效剂量施用于需要其的患者。 本发明还提供了一种筛选化合物的方法，所述化合物能够防止肌溶解性疾病的进展，并使用人H-PGDS过量表达的转基因小鼠进行改良。
-
4.发明申请Drugs for improving the prognosis of brain injury and a method of screening the same 审中-公开用于改善脑损伤预后的药物及其筛选方法公开(公告)号：US20050227984A1
公开(公告)日：2005-10-13
申请号：US11139530
申请日：2005-05-31
申请人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Yo Sato , Keiichi Kadoyama , Masako Taniike
发明人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Yo Sato , Keiichi Kadoyama , Masako Taniike
IPC分类号： A61K31/381 , A61K31/454 , A61K31/53 , A61K45/06 , A61P25/00 , A61P43/00 , C07D333/68 , G01N33/50 , G01N33/68 , G01N33/88 , A61K31/558
CPC分类号： A61K45/06 , A61K31/381 , A61K31/454 , A61K31/53 , G01N33/5088 , G01N33/6896 , G01N33/88
摘要： There are provided a compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease and a method for screening the same. Brain injury in which prostaglandin D2 is participated is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain injury area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area. There is also provided a method of testing those pharmaceutical substances using a transgenic mouse in which human hematopoietic prostaglandin D synthase is expressed in large amounts.
摘要翻译： 提供了治疗或预防由脑血管障碍，脑退行性疾病和脱髓鞘疾病等疾病引起的脑损伤的化合物及其筛选方法。 通过抑制由脑血管障碍，脑退行性疾病或脱髓鞘疾病等脑损伤区域的小胶质细胞或巨噬细胞诱导的造血前列腺素D合成酶来治疗或预防前列腺素D 2 2参与的脑损伤 或通过抑制在损伤区域周围的星形胶质细胞中表达的前列腺素D受体的活化来抑制。 还提供了使用其中大量表达人造血前列腺素D合成酶的转基因小鼠来测试这些药物的方法。
-
5.发明授权Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease 有权诊断嗜酸性炎症性疾病严重程度和复发预测的方法公开(公告)号：US08568967B2
公开(公告)日：2013-10-29
申请号：US11920543
申请日：2006-05-17
申请人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Sawako Hyo , Hiroshi Takenaka , Ryo Kawata
发明人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Sawako Hyo , Hiroshi Takenaka , Ryo Kawata
CPC分类号： G01N33/88 , A01K2217/05 , A01K2227/105 , A01K2267/0368 , C12N9/90 , C12N15/8509 , C12Q1/26 , G01N2800/24
摘要： A method is provided for diagnosis of the severity of a condition in an eosinophilic inflammatory disease such as nasal polyp and for prediction of the recurrence of the disease.
摘要翻译： 提供了一种用于诊断嗜酸性炎性疾病如鼻息肉中的病症严重程度并预测疾病复发的方法。
-
6.发明申请Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease 有权诊断嗜酸性炎症性疾病严重程度和复发预测的方法公开(公告)号：US20100138937A1
公开(公告)日：2010-06-03
申请号：US11920543
申请日：2006-05-17
申请人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Sawako Hyo , Hiroshi Takenaka , Ryo Kawata
发明人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Sawako Hyo , Hiroshi Takenaka , Ryo Kawata
CPC分类号： G01N33/88 , A01K2217/05 , A01K2227/105 , A01K2267/0368 , C12N9/90 , C12N15/8509 , C12Q1/26 , G01N2800/24
摘要： A method for diagnosis of the severity of a condition in an eosinophilic inflammatory disease such as nasal polyp or for prediction of the recurrence of the disease, the method comprising detecting H-PGDS induced by eosinophilic leukocytes accumulated in a lesion or determining pGD2 in a nasal alveolar lavage fluid or Bronchoalveolar lavage fluid
摘要翻译： 一种用于诊断嗜酸性炎性疾病如鼻息肉或用于预测疾病复发的病症严重程度的方法，所述方法包括检测积累在病变中的嗜酸粒细胞白血球诱导的H-PGDS或确定鼻中的pGD2 肺泡灌洗液或支气管肺泡灌洗液
-
7.发明授权Method for treating myolytic disease and method for screening antimyolytic agent 失效治疗溶血性疾病的方法和抗溶血剂筛选方法公开(公告)号：US07238718B2
公开(公告)日：2007-07-03
申请号：US10919473
申请日：2004-08-17
申请人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Yo Sato , Masako Taniike , Ikuko Mori , Masashi Miyano
发明人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Yo Sato , Masako Taniike , Ikuko Mori , Masashi Miyano
IPC分类号： A61K31/41 , A61K31/40 , A61K31/185
CPC分类号： G01N33/5088 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K31/47 , C12N15/8509 , C12N15/90 , G01N2800/2892 , G01N2800/324 , G01N2800/325
摘要： An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic prostaglandin D synthase (H-PGDS) or an antagonist to prostaglandin D receptor is administered to a patient who needs it. The present invention also provides a method for screening compounds which are able to prevent the progress of myolytic diseases and to improve it using human H-PGDS overexpressed transgenic mice.
摘要翻译： 本发明的目的是提供能够防止或改善诸如肌营养不良症的肌溶解性疾病进展的方法。 能够通过以下方法解决这样的问题：将有效剂量的造血前列腺素D合成酶（H-PGDS）抑制剂或前列腺素D受体拮抗剂的有效剂量施用于需要其的患者。 本发明还提供了一种筛选化合物的方法，所述化合物能够防止肌溶解性疾病的进展，并使用人H-PGDS过量表达的转基因小鼠进行改良。
-
公开(公告)号：US20050222235A1
公开(公告)日：2005-10-06
申请号：US10520781
申请日：2003-07-14
申请人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Yo Sato , Keiichi Kadoyama , Masako Taniike
发明人： Yoshihiro Urade , Naomi Eguchi , Kosuke Aritake , Yo Sato , Keiichi Kadoyama , Masako Taniike
IPC分类号： A61K31/381 , A61K31/454 , A61K31/53 , A61K45/06 , A61P25/00 , A61P43/00 , C07D333/68 , G01N33/50 , G01N33/68 , G01N33/88 , A61K31/4164 , A61K31/403
CPC分类号： A61K45/06 , A61K31/381 , A61K31/454 , A61K31/53 , G01N33/5088 , G01N33/6896 , G01N33/88
摘要： There are provided a compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease and a method for screening the same. Brain injury in which prostaglandin D2 is participated is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain injury area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area. There is also provided a method of testing those pharmaceutical substances using a transgenic mouse in which human hematopoietic prostaglandin D synthase is expressed in large amounts.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.021 秒)
